SQUAWK/NEWS
Account
Theme
Account
Menu
Live NewsCategoriesequity

Crescent Biopharma, Inc. (CBIO) News

Follow Crescent Biopharma, Inc. (CBIO) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 16 public stories across 12 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.

Symbol CBIO Asset equity Sector Markets 90 days 10 Last 13.045 Updated Oct 15, 2026, 08:15 PM UTC Open live news feed Open CBIO chart & news
L Crescent Biopharma expands CR-001 clinical studies Patients are enrolling in standard-of-care chemotherapy combination cohorts of the global Phase 1/2 ASCEND trial; additional ADC combination studies with CR-001 have begun. EQUITY | Oct 15, 2026, 08:15 PM UTC L Crescent Biopharma FDA clears IND for CR-002 Crescent Biopharma says the FDA cleared its IND application for CR-002, a PD-L1-targeted topoisomerase inhibitor ADC for solid tumors. EQUITY | Oct 05, 2026, 11:30 AM UTC L Crescent Biopharma Announces Grants of Inducement Awards WALTHAM, Mass., Sept. 25, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) NASDAQ:CBIO, a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for NEWS | Sep 25, 2026, 08:21 PM UTC L CBIO: Major clinical data for oncology assets expected in 2027, with strong cash runway and global strategy The company is advancing a robust oncology pipeline with a PD-1/VEGF bispecific and ADCs, supported by a global partnership and efficient clinical trial design. Major data readouts are expected in 2027, with strong finan NEWS | Sep 14, 2026, 11:44 PM UTC L CBIO: Global clinical trials and major data milestones in 2027 will drive next-gen oncology combinations A robust oncology pipeline is advancing, with global clinical trials for a PD-1/VEGF bispecific and ADCs, supported by a strategic partnership and strong financial position. Key data readouts are expected throughout 2027 NEWS | Sep 14, 2026, 11:23 PM UTC L CBIO: Key 2027 data from global oncology trials will drive phase III plans and registration strategies A robust oncology pipeline is advancing, with key data from global trials of a PD-1/VEGF bispecific and ADCs expected in 2027. Strategic partnerships, efficient trial design, and a strong cash position support rapid prog NEWS | Sep 14, 2026, 10:37 PM UTC L Crescent Biopharma announces grants of inducement awards WALTHAM, Mass., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) NASDAQ:CBIO, a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for EQUITY | Sep 09, 2026, 08:21 PM UTC L Crescent Biopharma management scheduled for September investor conferences Crescent Biopharma said management is scheduled to present at September investor conferences, according to a company announcement. EQUITY | Sep 03, 2026, 11:38 AM UTC L CBIO - Crescent Biopharma to Present at September Investor Conferences CBIO - Crescent Biopharma to Present at September Investor Conferences EQUITY | Sep 03, 2026, 11:30 AM UTC L Crescent Biopharma PT kept at $27 by Wedbush Wedbush maintained its Crescent Biopharma price target at $27.00 per share. EQUITY | Aug 27, 2026, 01:31 PM UTC L Crescent Biopharma Grants Inducement Awards Crescent Biopharma grants inducement awards EQUITY | Aug 03, 2026, 11:30 AM UTC L CBIO - Crescent Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights CBIO - Crescent Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights EARNINGS | Jul 30, 2026, 11:35 AM UTC L Deal priced today • QTTB 6.03M share Secondary, priced at $18.25, by MSCO, JEFF, Cantor, OPCO & HCW • CBIO 8.1M share Spot Secondary, priced Deal priced today • QTTB 6.03M share Secondary, priced at $18.25, by MSCO, JEFF, Cantor, OPCO & HCW • CBIO 8.1M share Spot Secondary, priced at $14.50, by JEFF, TD Cowen, GUGG, Cantor & LifeSci Deal postponed • TP (Ticke REGULATION | Jul 15, 2026, 12:21 PM UTC L Crescent Biopharma files ordinary shares offering, no amount given Crescent Biopharma files ordinary shares offering, no amount given EQUITY | Jul 14, 2026, 08:23 PM UTC L CBIO Crescent Biopharma announces proposed public offering of ordinary shares and pre-funded warrants CBIO Crescent Biopharma announces proposed public offering of ordinary shares and pre-funded warrants EQUITY | Jul 14, 2026, 08:01 PM UTC L Crescent Biopharma Files Prospectus For Offering $500M Mixed Shelf Crescent Biopharma Files Prospectus For Offering $500M Mixed Shelf EQUITY | Jul 01, 2026, 08:19 PM UTC